CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 115 filers reported holding CYTOMX THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 1.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $4,497,000 | +56.9% | 418,364 | +120.4% | 0.01% | +50.0% |
| Q4 2018 | $2,866,000 | -58.1% | 189,824 | -48.6% | 0.00% | 0.0% |
| Q3 2018 | $6,836,000 | +81.6% | 369,502 | +124.3% | 0.00% | -20.0% |
| Q2 2018 | $3,765,000 | -8.0% | 164,708 | +14.5% | 0.01% | 0.0% |
| Q1 2018 | $4,092,000 | +261.5% | 143,823 | +168.2% | 0.01% | +400.0% |
| Q4 2017 | $1,132,000 | +19.3% | 53,623 | +2.7% | 0.00% | 0.0% |
| Q3 2017 | $949,000 | +17.3% | 52,211 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $809,000 | +33.9% | 52,211 | +49.3% | 0.00% | 0.0% |
| Q1 2017 | $604,000 | +57.3% | 34,961 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $384,000 | -25.3% | 34,961 | +6.7% | 0.00% | 0.0% |
| Q3 2016 | $514,000 | +53.4% | 32,752 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $335,000 | +238.4% | 32,752 | +327.4% | 0.00% | – |
| Q1 2016 | $99,000 | -38.1% | 7,663 | 0.0% | 0.00% | – |
| Q4 2015 | $160,000 | – | 7,663 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 524,763 | $7,924,000 | 3.84% |
| Congress Park Capital LLC | 123,311 | $1,862,000 | 2.05% |
| Perceptive Advisors | 2,911,715 | $43,588,000 | 1.66% |
| RTW INVESTMENTS, LP | 908,586 | $13,720,000 | 1.28% |
| HAMILTON LANE ADVISORS LLC | 68,753 | $1,038,000 | 0.91% |
| HARBOURVEST PARTNERS LLC | 79,193 | $1,196,000 | 0.57% |
| SPHERA FUNDS MANAGEMENT LTD. | 273,151 | $4,125,000 | 0.46% |
| Exane Asset Management | 50,000 | $755,000,000 | 0.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 622,548 | $9,400,000 | 0.38% |
| Cormorant Asset Management, LP | 296,712 | $4,480,000 | 0.36% |